Actuate Therapeutics, Inc.
About
2.02USD-0.06 -2.88%
Closed • Updated at 06:51 GMT+00:00Market Cap$48.33M
Volume102.4K
Beta2.05
RSI33.93
Actuate Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 11 2026
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 6 2026
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
Apr 14 2026
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Mar 9 2026
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Mar 4 2026
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Community Chat
Ask AI
Try asking